Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean lactam acid and urea?
Displaying drugs 51 - 75 of 419 in total
A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Approved
Matched Synonyms: … 5-ethyl-1-methyl-5-phenylbarbituric acid
Matched Categories: … Barbiturates and Derivatives ... Hypnotics and Sedatives ... Phenobarbital and similars …
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Categories: … Urea Cycle Disorder Agents ... Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Approved
Vet approved
Matched Description: … [A188387] Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. ... [L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named …
Matched Mixtures name: … HYDROCORTISONE 1% ET UREA 5% CREAM ... Hydrocortisone and Acetic Acid ... Hydrocortisone and Acetic Acid
Matched Categories: … Alimentary Tract and Metabolism ... Sex Hormones and Insulins ... hydrocortisone and mydriatics ... Hydrocortisone and derivatives ... hydrocortisone and antiseptics …
Matched Products: … Rodan and Fields Soothe ... Itch and Rash Cream ... Up and Up Anti Itch …
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis...
Approved
Investigational
Matched Description: … drug whose main use is after organ transplant to reduce the activity of the patient's immune system and ... the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and ... This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL …
Matched Mixtures name: … Hyaluronic Acid Sodium Salt 1% / Tacrolimus 0.1% / Urea 20% ... Hyaluronic Acid Sodium Salt 1% / Niacinamide 4% / Tacrolimus 0.1% …
Matched Categories: … Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a …
Matched Mixtures name: … Ciclopirox 3% / Itraconazole 5% / Urea 20% ... Ciclopirox 0.77% / Salicylic Acid 2% ... Ciclopirox Olamine 1% / Salicylic Acid 2% …
Matched Categories: … Vaginal Creams, Foams, and Jellies ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and ... This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …
Matched Products: … Firmagon 120mg Powder and Solvent for Solution for Injection ... Firmagon 80mg Powder and Solvent for Solution for Injection ... FIRMAGON Powder and Solvent for Solution for Injection 120 mg …
Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine.[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in...
Approved
Matched Description: … [A187694] Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns ... Caffeine is similar in chemical structure to [Theophylline] and [Theobromine]. ... variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and
Matched Mixtures name: … C T Acetylsalicylic Acid Codeine and Caf Tab ... Acetylsalicylic Acid, Caffeine and 8 Mg Codeine Phosphate ... Acetylsalicylic Acid, Caffeine & 8 Mg Codeine Phosphate Tablets …
Matched Categories: … caffeine and sodium benzoate ... Respiratory and CNS Stimulants ... Caffeine and Caffeine Containing Products ... Anorexigenic Agents & Respiratory and CNS Stimulants ... Psychostimulants, Agents Used for ADHD and Nootropics …
Matched Products: … Caffeine and Sodium Benzoate …
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Description: … "boosts" lopinavir exposure and improves antiviral activity. ... Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and ... [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination …
Matched Mixtures name: … Lopinavir and Ritonavir ... Lopinavir and ritonavir ... Lopinavir and ritonavir …
Matched Categories: … lopinavir and ritonavir ... Metabolic Side Effects of Drugs and Substances …
Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not...
Approved
Investigational
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … Cetrotide 0.25 mg powder and solvent for solution for injection …
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Matched Iupac: … [2-(propan-2-yl)pent-4-enoyl]urea
Matched Categories: … Hypnotics and Sedatives …
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and ... two open-label trials which showed that the onset of action was approximately 1.0 hour and the median …
Matched Categories: … Gastric Acid Lowering Agents ... Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Iupac: … 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinan-5-yl)formamido]acetic acid
Matched Description: … HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Iupac: … -1-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … Ethotoin is a hydantoin derivative and anticonvulsant. ... The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Iupac: … 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Description: … long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. ... worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and ... present,[A177715] as they work by stimulating the release of insulin from the pancreatic beta cells and
Matched Mixtures name: … Pioglitazone and Glimepiride ... Pioglitazone and Glimepiride ... Pioglitazone hydrochloride and glimepiride …
Matched Categories: … Alimentary Tract and Metabolism ... glimepiride and pioglitazone ... glimepiride and rosiglitazone …
The administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)
Approved
Matched Description: … The administration of quinidine derivatives helps to observe various skin and mucosal reactions. ... without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … the growth of normal and malignant prostatic tissue. ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the...
Approved
Matched Description: … count, and neuropsychiatric effects [A19635]. ... for its high replicative rate and genetic diversity [A19594]. ... achieve a SVR between 93 and 99% after 12 weeks of treatment [A7535]. …
Matched Mixtures name: … Ledipasvir and Sofosbuvir ... Sofosbuvir and Velpatasvir …
Matched Categories: … sofosbuvir and ledipasvir ... sofosbuvir and velpatasvir ... sofosbuvir, velpatasvir and voxilaprevir ... Nucleic Acids, Nucleotides, and Nucleosides …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina ... It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 …
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of...
Approved
Investigational
Withdrawn
Matched Description: … It has once again been approved and should soon be available on the French and Australian market. …
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ... [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 51 - 75 of 419 in total